Key Highlights
- 9.55% is the indicated pre-market decline for IceCure Medical Ltd. (NASDAQ:ICCM) on November 18, 2026, to USD 0.7508 from a calculated prior close of USD 0.8300, a calculated move of USD 0.0792 lower.
- 18 is the November 2026 date of the company results release for the nine months ended September 30, 2026, scheduled before the Nasdaq open, with a conference call at 10:00 a.m. ET.
- 8.8 million is the first half 2026 net loss in USD for IceCure Medical Ltd. (NASDAQ:ICCM) in published coverage, while first half sales rose 45% and cash was about USD 12 million after an USD 8.5 million raise.
- 30 is the number of US active commercial sites reported as exceeded after the October 2025 FDA clearance, up from 19 the prior quarter, with gross Margin of about 30% in the first half.
What Moved IceCure Medical Ltd. (NASDAQ:ICCM) in Pre-Market Trading on November 18, 2026 (-USD 0.0792, -9.55%)
The indicated pre-market price of IceCure Medical Ltd. (NASDAQ:ICCM) on November 18, 2026 is USD 0.7508, a pre-market move of -9.55% ahead of the 9:30 a.m. ET open. On a calculated basis, the prior close from the November 17, 2026 regular session was USD 0.8300 (USD 0.7508 divided by 0.9045), and the USD move is -USD 0.0792 (price minus prior close). No pre-market Volume figure was found, and a market Capitalization could not be corroborated, so it is not stated.
The Rationale: Results Day Following the Nine-Month Release for IceCure Medical Ltd. (NASDAQ:ICCM)
The likely catalyst is the company release of financial and operating results for the nine months ended September 30, 2026, scheduled before the Nasdaq open on November 18, 2026, with a conference call at 10:00 a.m. ET. The date was announced on November 11, 2026. The reported figures could not be corroborated and are not stated, so the direction of the move cannot be tied to specific numbers. Published coverage had described the third quarter as seasonally softer, with the fourth quarter typically the strongest, and noted about USD 0.9 million of Revenue in the prior quarter. As general context, results days often bring sharp moves.
Valuation, Liquidity and Risks for IceCure Medical Ltd. (NASDAQ:ICCM)
IceCure makes liquid nitrogen cryoablation systems, and its ProSense system is FDA-cleared for local treatment of breast cancer in patients aged 70 and older with biologically low-risk tumors of 1.5 cm or less receiving adjuvant endocrine therapy. Published coverage cited a first half net loss of USD 8.8 million, cash of about USD 12 million and no formal guidance. The CHOICE trial targets 30 sites and 80 patients by March 2027, and reimbursement benefits are not expected until around early 2028. Nasdaq granted a 180-day extension in May 2026 to regain minimum bid compliance, and the indicated price is a calculated 24.92% below USD 1.00.
Where Things Stand
IceCure Medical Ltd. (NASDAQ:ICCM) is indicated at USD 0.7508 in pre-market trading on November 18, 2026, a move of -9.55% from a calculated prior close of USD 0.8300, on the day the company releases results for the nine months ended September 30, 2026. Reported figures were not corroborated for this article. Published coverage pointed to first half revenue growth of 45%, a net loss of USD 8.8 million and cash of about USD 12 million. Bid price compliance, cash needs and the pace of CHOICE trial enrollment are the central risks. This article is informational and is not Investment advice.


_11_18_2026_12_49_56_510703.jpg)


_11_18_2026_12_55_06_251523.jpg)
Please wait processing your request...